Biotech | October 13, 2021
Roche’s 8-year safety data of Ocrevus shows reduced risk in multiple sclerosis patients
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
The company plans to raise US $ 15 million
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
Since its inception, the company has either acquired or taken a majority stake in five companies
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
In collaboration with RAND Europe, the Vitality calculator predicts an individual's healthspan and future health risks
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
The drug is being developed at lab scale for the first-line of treatment of Covid-19
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
Subscribe To Our Newsletter & Stay Updated
